Correspondence 0001193125-24-145160 from Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) (LRMR)
Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)
Date: May 22, 2024 · CIK: 0001374690 · Accession: 0001193125-24-145160
AI Filing Summary & Sentiment
File numbers found in text: 333-279275
Letter
Larimar Therapeutics, Inc.
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania 19004
May 22, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-7553
Re: Larimar Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 9, 2024 (File No. 333-279275)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-279275) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 P.M., Eastern Time, on May 24, 2024, or as soon thereafter as is practicable.
Please contact Jennifer L. Porter, Esq. of Goodwin Procter LLP, counsel to the Company, at (445) 207-7806 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]
Very truly yours,
LARIMAR THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 May 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Larimar Therapeutics, Inc. Registration Statement on Form S-3 Filed May 9, 2024 (File No. 333-279275) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-279275) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 P.M., Eastern Time, on May 24, 2024, or as soon thereafter as is practicable. Please contact Jennifer L. Porter, Esq. of Goodwin Procter LLP, counsel to the Company, at (445) 207-7806 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [Remainder of the page intentionally left blank] Very truly yours, LARIMAR THERAPEUTICS, INC. By: /s/ Carole Ben-Maimon, M.D. Name: Carole Ben-Maimon, M.D. Title: President and Chief Executive Officer